Tesofensine
Triple Reuptake Inhibitor
Tesofensine is a novel triple monoamine reuptake inhibitor that works on serotonin, norepinephrine, and dopamine pathways—completely different from GLP-1 medications. Phase 2 trials showed up to 10.6% weight loss in 24 weeks, with effects on both appetite suppression and resting energy expenditure.
The Science
What is Tesofensine?
Tesofensine is a triple monoamine reuptake inhibitor—it blocks the reabsorption of serotonin, norepinephrine, and dopamine in the brain. This is a completely different mechanism from GLP-1 medications, working directly on brain neurotransmitter systems that regulate appetite, satiety, and energy expenditure.
Originally developed for Parkinson’s and Alzheimer’s disease, tesofensine was repurposed for obesity after clinical trials consistently showed significant weight loss as a “observed effect.” By modulating dopamine and serotonin pathways, it reduces food cravings and enhances feelings of fullness while potentially increasing resting metabolic rate.
Phase 3 trials are ongoing.
Mechanism of Action
The Triple Reuptake Mechanism
Tesofensine works by blocking the reabsorption of three key neurotransmitters involved in appetite and energy regulation.
Serotonin Reuptake Inhibition
Increases serotonin availability in the brain, enhancing satiety signals and reducing cravings—similar to how SSRIs work but with additional pathways.
Norepinephrine Reuptake Inhibition
Boosts norepinephrine levels, potentially increasing resting energy expenditure and fat oxidation while suppressing appetite.
Dopamine Reuptake Inhibition
Modulates the reward pathway to reduce the pleasure drive for food consumption, making it easier to resist cravings and emotional eating.
Different Mechanism
Works on brain neurotransmitter systems (serotonin, dopamine, norepinephrine) rather than gut hormones—a completely distinct pathway from GLP-1 medications.
Dual Action
Both suppresses appetite and potentially increases resting energy expenditure—addressing weight from both calorie intake and metabolic rate angles.
Craving Reduction
Dopamine pathway modulation may help reduce food cravings and emotional eating—addressing the psychological aspects of overeating.
Mood Benefits
Increased BDNF levels and serotonin/dopamine activity may provide mild mood-enhancing effects alongside weight loss.
FAQ
Frequently Asked Questions
Is tesofensine FDA approved?+
No, tesofensine is not yet FDA approved. It has completed Phase 2 clinical trials with Phase 3 trials ongoing. The timeline for FDA approval remains uncertain. Until approved, tesofensine is not available for commercial sale.
Research-Only Notice
Tesofensine is categorized by the FDA as for research-purposes-only. It is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease. The information above summarizes effects observed in laboratory studies to date and is provided strictly for scientific and educational reference.